Shandong Weigao Group Medical Polymer Company Limited
Shandong Weigao Group Medical Polymer Company Limited, commonly referred to as Weigao, is a leading player in the medical device industry, headquartered in Shandong, China. Established in 1988, the company has grown significantly, expanding its operations across various regions, including Asia, Europe, and North America. Weigao specialises in the development and manufacturing of high-quality medical polymer products, including intravenous (IV) products, surgical instruments, and diagnostic devices. Their commitment to innovation and quality has positioned them as a trusted supplier in the healthcare sector. Notably, Weigao has achieved several milestones, including numerous certifications and awards that underscore its dedication to excellence and safety in medical technology. With a strong market presence, Weigao continues to enhance patient care through its advanced medical solutions.
DitchCarbon Score
How does Shandong Weigao Group Medical Polymer Company Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Shandong Weigao Group Medical Polymer Company Limited's score of 25 is higher than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Shandong Weigao Group Medical Polymer Company Limited's reported carbon emissions
In 2023, Shandong Weigao Group Medical Polymer Company Limited reported total carbon emissions of approximately 102,578,650 kg CO2e, comprising 2,704,870 kg CO2e from Scope 1 and 99,528,780 kg CO2e from Scope 2 emissions. The company has not disclosed any Scope 3 emissions data for this year. In 2022, the company recorded total emissions of about 104,204,940 kg CO2e, with Scope 1 emissions at 2,978,680 kg CO2e and Scope 2 emissions at 101,426,260 kg CO2e. Over the years, Shandong Weigao has shown fluctuations in its emissions, with a notable decrease in Scope 1 emissions from 28,464,480 kg CO2e in 2021 to 2,704,870 kg CO2e in 2023. However, there are no specific reduction targets or climate pledges disclosed by the company, indicating a potential area for improvement in their climate commitments. The company’s emissions intensity has also varied, with a reported intensity of approximately 26,520 kg CO2e per unit of revenue in 2023. As a significant player in the medical polymer industry, Shandong Weigao's emissions and climate strategies are crucial for aligning with global sustainability goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 93,645,660 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 31,460 | 00,000,000 | 000,000,000 | 00,000,000 |
| Scope 3 | 819,150 | 0,000,000 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Shandong Weigao Group Medical Polymer Company Limited is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
